- $116.26m
- $145.26m
- $94.64m
Recro Pharma Inc reports results for the quarter ended in June - Earnings Summary
Recro Pharma Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: RecroP harma Appoints Erica Raether As Vice President Of People, Culture And ESG
Brief: Recro Enters Development And Manufacturing Agreement With New Client
Brief: Recro Appoints Laura L. Parks, Ph.D. To Board Of Directors
Brief: Recro Expands Capabilities For Growing Clinical Trial Services (CTS) Offerings
Brief: Recro Enters Development Agreement With Astex Pharmaceuticals
Recro Pharma slumps on $30 mln stock deal
Brief: Recro Pharma Announces Pricing Of $30.0 Million Public Offering Of Common Stock
Brief: Recro Announces Proposed Public Offering Of Common Stock
Recro Pharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Recro Reports First Quarter 2021 Financial Results
Recro Pharma Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Recro Expands Development And Manufacturing Relationship With Ensysce Biosciences
Brief: Recro Pharma Inc Files For Mixed Shelf Of Up To $100 Million
Recro Pharma: Tumbles as Q4 revenue falls, net loss widens
Brief: Recro Reports Fourth Quarter And Year End 2020 Results
Brief: Recro Announces Amendment To Athyrium Credit Facility
U.S. RESEARCH ROUNDUP- American Woodmark, Comtech Telecommunications, Mohawk Group Holdings